The global glycomics/glycobiology market size was estimated at USD 645.7 million in 2016.
Technological advancements in glycomics instruments are expected to be a major factor driving the market growth.
Rising investments on research by government along with escalating focus of pharmaceutical and biotechnology companies on novel drug development are other major factors contributing toward growth of the sector. For instance, in February 2015, government of Canada announced the federal funding of around USD 27.3 million for a national research network, namely GlycoNet, to develop new vaccines and drugs for various medical conditions, including genetic diseases, influenza, and diabetes.
U.S. glycomics/glycobiology market, by product, 2014 - 2025 (USD million)
Glycobiology is an important field in life sciences and involves the study of glycans that play diverse roles in study of bacterial physiology, novel drugs development, and proteomics research. Various technologies such as mass spectrometry, High performance Liquid Chromatography (HPLC), and MALDI-TOF (Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry) are used by researchers for glycomics application. Thus, the demand for glycobiology instruments, including mass spectrometers and MALDI-TOF mass spectrometry, is expected to increase in the near future.
Stringent government policies and regulations for the development & manufacturing of diagnostic devices including mass spectrometry, MALDI-TOF mass spectrometry, and HPLC could hinder the growth of the market. Commercialization of in vitro diagnostic instruments and other consumables is depends on successful completion of preclinical and clinical trials, which is a long, expensive, and uncertain process. Delays or rejections of potential products could cause a significant rise in the costs incurred by the manufacturer.
In 2016, the instruments segment was the largest revenue-generating segment due to advancements and high price of the instruments. In addition, increasing application of glycomics instruments, including mass spectrometers, HPLC, MALDI-TOF mass spectrometry, and array systems for drug discovery & development and oncology research is expected to boost the growth.
Development of novel technologies along with continuous improvements in the existing products are steering market growth. For instance, in June 2016, Bruker launched its new rapifleX MALDI PharmaPulse solution for pharmaceutical, biotechnology, and Contract Research Organizations (CROs), which is expected to accelerate drug discovery & development and lower the cost of ultra-high throughput screening with improved results.
Enzymes emerged as the second largest revenue grossing segment of glycobiology market in 2016. The large application of enzymes in glycomics research, diagnostics, and drug discovery was one of the primary factors that helped develop its market in the past.
The enzyme segment is also expected to grow at the highest rate during the forecast period owing to rising focus of biotechnology companies and research institutes in a variety of drug discovery and R&D procedures. Also, the repetitive purchase of enzymes for various applications, including drug discovery, diagnostics, oncology research, and immunology study, is expected to propel the segment growth.
The drug discovery & development segment dominated the glycomics market in terms of revenue in 2016. This is due to the rising demand for effective drugs and personalized medicine globally. The pharmaceutical and biotechnology companies are investing large amount of money in R&D for novel drug development.
Glycomics involves the study of functions and structures of glycans in biological systems. Thus, it can be used in the field of personalized medicine for early detection of diseases, to select suitable treatment, and to develop personalized drug. Glycomics can considerably complement the proteomics and genomics tools, which are already being used for developing personalized medicines.
Diagnostics is the second largest revenue-generating segment of the glycomics sector in 2016. The high prevalence of patients suffering from chronic diseases such as heart disease, diabetes, cancer, stroke, and arthritis is the major growth driver of this segment. As stated by CDC, around 29.1 million people in the U.S. were suffering from diabetes in 2016. Thus, the application of glycomics products for disease diagnosis is expected to rise in near future.
The U.S., Germany, U.K., France, Japan, China, and India are projected to account for the highest application of glycomics. Availability of glycobiology products in these countries along with the presence of a large number of biotechnology and pharmaceutical companies in these countries is expected to contribute toward growth.
North America glycomics market share, by application, 2016 (%)
The academic & research institutes accounted for the largest revenue share in the glycobiology market. This is due to the increased focus on glycomics, proteomics, and other life sciences related research. This segment is expected to grow at a profitable CAGR during forecast period.
The increased funding by governments on biotechnology industry is another major factor contributing to the growth of the academic & research institute segment. For instance, in September 2015, GlycoNet (The Canadian Glycomics Network) has awarded 17 research grants that accounted for around USD 9.6 million for glycomics research. These grants will support researches that have a wide range of applications on human health, including novel drug development to treat staph infections and development of effective therapy for oncology, lysosomal storage diseases, & other genetic diseases.
The pharmaceutical & biotechnology companies segment is projected to have highest growth rate over the forecast period owing to increased investment on R&D by biotechnology and pharmaceutical companies. For instance, Agilent Technologies, a leading vendor of glycomics, invested around USD 329 million on R&D for advance product development.
Developing healthcare infrastructure and high per capita income have spurred the demand for advanced products for diagnosis and treatment. Glycomics plays an important role in personalized medicine development and study of bacterial physiology. Thus, demand for glycomics instruments and consumables is expected to increase in the near future.
North America dominated the glycomics market with the largest revenue share, due to the presence of many large pharmaceutical and biotechnology companies such as Danaher; Thermo Fisher Scientific, Inc.; Merck KGaA; and Agilent Technologies in this region. Moreover, the highly developed healthcare infrastructure and availability of advanced products in this region have also fueled growth.
North America was followed by Europe in terms of revenue in 2016. Growing medical and life sciences research activities as well as local presence of big pharmaceutical manufacturers, mainly in Germany, UK, Switzerland, and France, coupled with highly developed healthcare infrastructure are expected to remain major driving factors for the growth of the market.
Asia Pacific region is projected to grow at the highest CAGR during the forecast period, owing to growing penetration of CROs and developing healthcare infrastructure in growing Asian countries like India and China. The availability of a large number of patients, low cost for conducting clinical trials, massive genome pool, and accessibility of skilled personnel in Asian countries have propelled the growth of the market in this region.
The global glycomics market is highly fragmented with the presence of a large number of manufacturers. Several big vendors including Thermo Fisher Scientific, Inc.; Danaher; Agilent Technologies; ProZyme; Bruker; Merck KGaA; Shimadzu Corporation; Takara Bio, Inc.; New England Biolabs; and Waters Corporation share the market with other medium- and small-sized vendors.
The leading manufacturers deliver an extensive range of innovative glycobiology products through their strong distribution channels across the globe. It has resulted in intense competition amongst vendors and led to high pressure on pricing strategies of manufacturers, which is expected to have negative impact on the profit margin.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million & CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America & MEA
U.S., Canada, Germany, UK, Japan, India, China, Brazil, Mexico, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
Segments covered in the report
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global glycomics/glycobiology market on the basis of product, application, end use, and region:
Product Outlook (Revenue, USD Million; 2014 - 2025)
Glycan labeling kits
Glycan purification kits
Glycan release kits
Application Outlook (Revenue, USD Million; 2014 - 2025)
Drug discovery & development
End-use Outlook (Revenue, USD Million; 2014 - 2025)
Academic and research institutes
Pharmaceutical and biotechnology companies
Regional Outlook (Revenue, USD Million; 2014 - 2025)
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.